Key facts
- This page summarizes RedCo II Master Fund, L.P.'s Form 3 filing for Augmedix, Inc..
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 May 2023, 21:30.
RedCo II Master Fund, L.P. - 02 May 2023 Form 3 Insider Report for Augmedix, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 02 May 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 04 May 2023, 21:30:25 UTC
- Prior SEC filing
- 06 Apr 2022
- Next SEC filing
- 03 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeremy Green, Managing Member of RedCo II (GP), LLC, general partner of RedCo II Master Fund, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RedCo II Master Fund, L.P. filed Form 3 for Augmedix, Inc. on 04 May 2023.
Change
- Previous filing in this sequence was filed on 06 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUGX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,696,146
- Date
- 02 May 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AUGX
holding
Derivative
Pre-Funded Warrants to Purchase Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,125,195
- Exercise price
- $0.000100
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Redmile Group, LLC ("Redmile") has filed a Form 4 concurrently with RedCo II Master Fund, L.P.'s ("RedCo II") filing of this Form 3 to report Redmile's indirect beneficial ownership of the Common Stock.
Footnote F2
The Pre-Funded Warrants are exercisable by the holder at any time on or after the date of the securities purchase agreement between Augmedix, Inc. (the "Issuer") and certain stockholders, including RedCo II Master Fund, L.P., dated as of April 19, 2023, until fully exercised at an exercise price of $0.0001 per Pre-Funded Warrant share, subject to a limitation on the right of the Issuer to issue the Pre-Funded Warrant shares if and to the extent that such exercise would violate the rules or regulations of Nasdaq Stock Market LLC. The Pre-Funded Warrants have no expiration date.
Footnote F3
Redmile filed a Form 4 on April 21, 2023 to report its indirect beneficial ownership of the Pre-Funded Warrants.
SEC remarks
Rob Faulkner, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Person is a director by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.